

Amy D Shapiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8532133/publications.pdf>

Version: 2024-02-01

77
papers

5,738
citations

159585

30
h-index

74163

75
g-index

80
all docs

80
docs citations

80
times ranked

3259
citing authors

#	ARTICLE	IF	CITATIONS
1	Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States. <i>Haemophilia</i> , 2022, 28, .	2.1	3
2	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) â€“ Unmet needs remain. <i>Haemophilia</i> , 2022, 28, 453-461.	2.1	5
3	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 Tj ETQq1 1,0,784314 rgBT /O	2.1	7
4	Therapeutic and technological advancements in haemophilia care: Quantum leaps forward. <i>Haemophilia</i> , 2022, 28, 77-92.	2.1	8
5	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). <i>Haemophilia</i> , 2021, 27, 49-59.	2.1	6
6	Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Realâ€world experience from a large comprehensive treatment centre in the US. <i>Haemophilia</i> , 2021, 27, 90-99.	2.1	37
7	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. <i>Haemophilia</i> , 2021, 27, 19-25.	2.1	6
8	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. <i>Haemophilia</i> , 2021, 27, 854-865.	2.1	21
9	The Bâ€Natural studyâ€”The outcome of immune tolerance induction therapy in patients with severe haemophilia B. <i>Haemophilia</i> , 2021, 27, 802-813.	2.1	11
10	Haemophilia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 45.	30.5	103
11	Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in <i>SERPINE1</i>. <i>JAMA Cardiology</i> , 2021, 6, 841.	6.1	8
12	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. <i>Blood Advances</i> , 2021, 5, 2732-2739.	5.2	11
13	Concizumab: a novel anti-TFPI therapeutic for hemophilia. <i>Blood Advances</i> , 2021, 5, 279-279.	5.2	17
14	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. <i>Haemophilia</i> , 2021, 27, 921-931.	2.1	7
15	Final Results of the Prospective ADVATEÂ® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 991-1001.	1.7	0
16	The use of prophylaxis in the treatment of rare bleeding disorders. <i>Thrombosis Research</i> , 2020, 196, 590-602.	1.7	23
17	Realâ€world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5Âyears. <i>Haemophilia</i> , 2020, 26, 975-983.	2.1	12
18	Adherence is a human behaviour, assessing it requires multimethod evaluation with validated measures: Comment on Guedes VG et al (2019). <i>Haemophilia</i> , 2020, 26, 934-936.	2.1	3

#	ARTICLE	IF	CITATIONS
19	Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the OND extension study. <i>Haemophilia</i> , 2020, 26, e262-e271.	2.1	28
20	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. <i>Blood Advances</i> , 2020, 4, 2451-2459.	5.2	67
21	An international registry of patients with plasminogen deficiency (HISTORY). <i>Haematologica</i> , 2020, 105, 554-561.	3.5	13
22	Potential of the Community Counts registry to characterize rare bleeding disorders. <i>Haemophilia</i> , 2019, 25, 1045-1050.	2.1	11
23	Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. <i>Transfusion and Apheresis Science</i> , 2019, 58, 578-589.	1.0	17
24	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. <i>Lancet Haematology</i> , 2019, 6, e295-e305.	4.6	252
25	Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 849-857.	3.8	13
26	Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors: A retrospective analysis. <i>Haemophilia</i> , 2018, 24, 245-252.	2.1	39
27	Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. <i>Blood</i> , 2018, 131, 1301-1310.	1.4	27
28	The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2362-2374.	3.8	50
29	Recommendations on multidisciplinary management of elective surgery in people with haemophilia. <i>Haemophilia</i> , 2018, 24, 693-702.	2.1	60
30	Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients. <i>Haemophilia</i> , 2018, 24, 807-814.	2.1	10
31	BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. <i>Blood</i> , 2018, 132, 636-636.	1.4	11
32	Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 97-104.	3.3	25
33	Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in LONG study subjects with severe haemophilia A. <i>Haemophilia</i> , 2017, 23, 392-399.	2.1	9
34	The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States. <i>Haemophilia</i> , 2017, 23, e287-e293.	2.1	28
35	A null mutation in <i>SERPINE1</i> protects against biological aging in humans. <i>Science Advances</i> , 2017, 3, ea01617.	10.3	95
36	A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2017, 23, 810-811.	2.1	2

#	ARTICLE	IF	CITATIONS
37	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. <i>Thrombosis and Haemostasis</i> , 2017, 117, 508-518.	3.4	31
38	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FIQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1603-1612.	1.8	15
39	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1822-1828.	1.5	8
40	Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency. <i>Haemophilia</i> , 2016, 22, 419-425.	2.1	25
41	Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. <i>Haemophilia</i> , 2016, 22, 426-432.	2.1	17
42	Response to Gringeri <i>et al</i> .: "recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis" new insight provided by pharmacokinetic modelling™. <i>Haemophilia</i> , 2015, 21, e489-92.	2.1	1
43	Rare bleeding disorders: diagnosis and treatment. <i>Blood</i> , 2015, 125, 2052-2061.	1.4	244
44	Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. <i>British Journal of Haematology</i> , 2015, 168, 113-123.	2.5	31
45	Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two US centres. <i>Haemophilia</i> , 2015, 21, 365-373.	2.1	41
46	Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. <i>Haemophilia</i> , 2015, 21, 791-798.	2.1	9
47	Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 µg/kg ¹) rFVIIa doses across clinical trials and registries. <i>Haemophilia</i> , 2014, 20, e23-31.	2.1	14
48	Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications?. <i>Haemophilia</i> , 2014, 20, e367-e371.	2.1	3
49	Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. <i>Haemophilia</i> , 2014, 20, 616-623.	2.1	32
50	Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1287-1297.	3.1	33
51	Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. <i>Blood</i> , 2012, 119, 666-672.	1.4	167
52	Modern haemophilia care. <i>Lancet, The</i> , 2012, 379, 1447-1456.	18.7	266
53	U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors. <i>Haemophilia</i> , 2012, 18, 400-405.	2.1	14
54	Knowledge and Therapeutic Gaps. <i>American Journal of Preventive Medicine</i> , 2011, 41, S324-S331.	3.0	13

#	ARTICLE	IF	CITATIONS
55	VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. <i>Haemophilia</i> , 2010, 16, 247-255.	2.1	104
56	Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease. <i>Blood</i> , 2010, 116, 237-237.	1.4	2
57	Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 273-283.	3.1	31
58	Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 217-223.	3.4	60
59	Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 579-86.	0.3	14
60	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. <i>New England Journal of Medicine</i> , 2007, 357, 535-544.	27.0	1,681
61	Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. <i>Vascular Health and Risk Management</i> , 2007, 3, 555-65.	2.3	32
62	The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. <i>Blood</i> , 2005, 105, 518-525.	1.4	83
63	Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. <i>Haemophilia</i> , 2005, 11, 571-582.	2.1	60
64	Prevalence of elevated antithyroid antibodies and antinuclear antibodies in children with immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2005, 79, 175-179.	4.1	34
65	Why is primary prophylaxis underutilized in the United States?. <i>Haemophilia</i> , 2003, 9, 670-672.	2.1	13
66	Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. <i>Haemophilia</i> , 1999, 5, 101-105.	2.1	92
67	Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery. <i>Thrombosis and Haemostasis</i> , 1998, 80, 773-778.	3.4	365
68	Clinical evaluation of recombinant factor IX. <i>Seminars in Hematology</i> , 1998, 35, 33-8.	3.4	88
69	Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene. <i>Blood</i> , 1997, 90, 204-208.	1.4	215
70	Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene. <i>Blood</i> , 1997, 90, 204-208.	1.4	70
71	Safety and Efficacy of Monoclonal Antibody Purified Factor IX Concentrate in Previously Untreated Patients with Hemophilia B. <i>Thrombosis and Haemostasis</i> , 1996, 75, 030-035.	3.4	28
72	Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. <i>International Factor Safety Study Group. Transfusion</i> , 1995, 35, 204-208.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Safety of high doses of a monoclonal antibody-purified factor IX concentrate. American Journal of Hematology, 1995, 49, 92-94.	4.1	7
74	Variability of In Vivo Recovery of Factor IX after Infusion of Monoclonal Antibody Purified Factor IX Concentrates in Patients with Hemophilia B. Thrombosis and Haemostasis, 1995, 73, 779-784.	3.4	25
75	Long-term surveillance of HIV, HBV, and HCV infected patients. Annals of Hematology, 1994, 68, S87-S88.	1.8	1
76	A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 1994, 83, 2428-35.	1.4	305
77	Complete Deficiency of Plasminogen-Activator Inhibitor Type 1 Due to a Frame-Shift Mutation. New England Journal of Medicine, 1992, 327, 1729-1733.	27.0	274